Physician profile
William Wu
NPI 1346246626
$72,076.43
in general payments reported to CMS, 2019-2025
38 companies · $26K in 2025
The $26K reported for 2025 was more than what 97% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $797 · 2020: $263 · 2021: $636 · 2022: $846 · 2023: $13K · 2024: $31K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $67K · Food and Beverage: $2,951.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $66,583.33 |
| Food and Beverage | $2,950.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $66,969.57 | 2023-2025 | Auryon Laser System 100-120 Vac, Auryon Laser System 100-120 Vac |
| Novo Nordisk INC | $567.36 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $550.29 | 2019-2025 | Eliquis, Camzyos |
| Abbott Laboratories | $386.20 | 2019-2025 | Gallant, Aveir, Diamondback Peripheral |
| Esperion Therapeutics, INC. | $303.83 | 2020-2023 | Nexletol |
| Lilly USA, LLC | $296.28 | 2022-2025 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $276.41 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $255.59 | 2019-2025 | Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $253.34 | 2019-2025 | Lifevest |
| Amgen INC. | $219.01 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $200.83 | 2020-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.73 | 2022-2025 | Jardiance |
| Medtronic Vascular, INC. | $177.36 | 2019 | |
| Abiomed | $150.00 | 2022 | |
| Scpharmaceuticals INC. | $134.55 | 2024-2025 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $131.94 | 2021-2025 | Verquvo |
| Allergan, INC. | $124.95 | 2019 | |
| Novartis Pharmaceuticals Corporation | $113.51 | 2024-2025 | |
| Irhythm Technologies, INC. | $102.38 | 2023 | Zio Xt Patch |
| Biotronik INC. | $101.84 | 2019-2025 | Passeo-18, Pulsar-18 T3 |
| Boston Scientific Corporation | $92.75 | 2023-2025 | Watchman Flx, Cds - Mct/Cem Monitoring |
| Lexicon Pharmaceuticals, INC. | $79.55 | 2024 | |
| Glaxosmithkline, LLC. | $53.60 | 2019 | |
| Acist Medical Systems, INC. | $46.76 | 2022 | |
| Amarin Pharma, INC. | $35.47 | 2020 | |
| Sanofi-Aventis U.S. LLC | $32.92 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.23 | 2024 | |
| Teleflex LLC | $25.50 | 2025 | Manta |
| Reflow Medical INC | $24.49 | 2025 | |
| Philips North America LLC | $23.58 | 2022 | |
| Braemar Manufacturing, LLC | $23.56 | 2019 | |
| Alnylam Pharmaceuticals INC. | $19.01 | 2025 | Onpattro |
| Medicomp INC | $18.72 | 2021 | |
| G Medical Diagnostic Services, INC. | $15.12 | 2023 | Cardiac Monitoring Suite |
| Cardiovascular Systems INC. | $14.57 | 2021-2022 | |
| Cvrx, INC. | $14.08 | 2024-2025 | Barostim Neo System |
| Kiniksa Pharmaceuticals, Ltd. | $12.95 | 2023 | Arcalyst |
| Cashflow Solutions, LLC | $9.60 | 2024 | Lympha Press Optimal Plus(US) Bt, Pcd-52 737a (US) White, Pcd-51 731a (US) - White |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.